(Reuters) -British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for ...

The chronic lymphocytic leukemia therapeutics market is expected to grow at a compound annual growth rate of 7% from 2025 to ...

Urgent need for standardization in dental education and clinical practices: Dr Ashok Dhoble: Shardul Nautiyal, Mumbai Monday, ...

Irritable Bowel Syndrome Treatment Market PORTLAND, OR, UNITED STATES, August 11, 2025 /EINPresswire / -- The global irritable bowel syndrome ...

Detailed price information for Ideaya Biosciences Inc (IDYA-Q) from The Globe and Mail including charting and trades.

Gepotidacin was approved by the FDA earlier this year, under the Blujepa brand, as the first oral antibiotic to offer a new ...

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

Assembly Biosciences is advancing its herpes drug to Phase II trials after it showed 94% antiviral efficacy in a Phase Ib ...

Discover why some biotechs fail but survive with cash on hand, and how players like Concentra are trying to unlock trapped ...

GSK (GSK) stock in focus as the company bid to expand use of oral antibiotic agent gepotidacin for urogenital gonorrhea is granted FDA priority review. Read more here.

Harvey Jones takes a look at 2 FTSE 100 income stocks that investors are snubbing right now to see whether there's a big ...

GSK plc's experimental antibiotic, gepotidacin, has been granted priority review by the U.S. Food and Drug Administration ...